Novo nordisk a/s: alhemo® recommended for european approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia a or b with inhibitors

BagsvÆrd, denmark, 18 october 2024 – novo nordisk today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion, recommending approval of alhemo® (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia a or b with inhibitors.
NVO Ratings Summary
NVO Quant Ranking